Catherine Novak

“I'm just curious if you can give any additional expectations and what kind of dose response you would expect from 400 to 600 mix monthly based on prior modeling data and exposure and whether this is an opportunity that you can use to explore whether the MZ ratio can further improve with multi-dose regimen.”

“I just wanted to drill down on expectations for monotherapy body weight loss for O07 in patients with type 2 diabetes. You know, we've seen combination data with incretins showing inhibiting knockdown might help sensitize patients to therapy.”

“And then, you know, again, going back to indications outside of CSU, curious your thoughts, specifically your thoughts on migraine based on recent LUMBEC data looking at the MRG PRX2 pathway in migraine.”

“Just one for me on the dose response and relationship between activity and fat loss. So clinically, you are seeing similar fat loss to a competitor with lower activity knockdown.”

“I just want to ask a little bit, maybe some about some of the data that you showed at NANETS last week. Very interesting to see the PFS data in NANETS patients with PAL2, the team that is.”